Table 3.
Summary of adverse event disutilities from included studies
| Author (year), Country | Population | Adverse event | Disutility estimate | Instrument |
|---|---|---|---|---|
| Revicki and Wood [33], Canada and United States | Patients with MDD who had completed at least 8 weeks of ADT or had completed an ADT regimen within the last 2 months prior to the study | Sedation | 0.06a | Standard gamble (patients) |
| Nervousness | 0.12 | |||
| Headache | 0.09a | |||
| Constipation | 0.05a | |||
| Tension | 0.035a | |||
| Lightheaded/faint | 0.12 | |||
| Dry mouth | 0.01 | |||
| Nausea | 0.01 |
ADT Antidepressant Treatment, MDD Major Depressive Disorder
aDisutilities were calculated